Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Mar;31(2):204-214.
doi: 10.1111/vec.13034. Epub 2021 Mar 10.

The role of cryoprecipitate in human and canine transfusion medicine

Jennifer Prittie  1
Affiliations
Review

The role of cryoprecipitate in human and canine transfusion medicine

Jennifer Prittie. J Vet Emerg Crit Care (San Antonio). 2021 Mar.

Abstract

Objective: To evaluate the current role of cryoprecipitate in human and canine transfusion medicine.

Data sources: Human and veterinary scientific reviews and original studies found using PubMed and CAB Abstract search engines were reviewed.

Human data synthesis: In the human critical care setting, cryoprecipitate is predominantly used for fibrinogen replenishment in bleeding patients with acute traumatic coagulopathy. Other coagulopathic patient cohorts for whom cryoprecipitate is recommended include those undergoing cardiovascular or obstetric procedures or patients bleeding from advanced liver disease. Preferential selection of cryoprecipitate versus fibrinogen concentrate (when available) is currently being investigated. Also a matter of ongoing debate is whether to administer this product as part of a fixed-dose massive hemorrhage protocol or to incorporate it into a goal-directed transfusion algorithm applied to the individual bleeding patient.

Veterinary data synthesis: Although there are sporadic reports of the use of cryoprecipitate in dogs with heritable coagulopathies, there are few to no data pertaining to its use in acquired hypofibrinogenemic states. Low fibrinogen in dogs (as in people) has been documented with acute traumatic coagulopathy, advanced liver disease, and disseminated intravascular coagulation. Bleeding secondary to these hypocoagulable states may be amenable to cryoprecipitate therapy. Indications for preferential selection of cryoprecipitate (versus fresh frozen plasma) remain to be determined.

Conclusions: In the United States, cryoprecipitate remains the standard of care for fibrinogen replenishment in the bleeding human trauma patient. Its preferential selection for this purpose is the subject of several ongoing human clinical trials. Timely incorporation of cryoprecipitate into the transfusion protocol of the individual bleeding patient with hypofibrinogenemia may conserve blood products, mitigate adverse transfusion-related events, and improve patient outcomes. Cryoprecipitate is readily available, effective, and safe for use in dogs. The role of this blood product in clinical canine patients with acquired coagulopathy remains unknown.

Keywords: acute traumatic coagulopathy; fibrinogen; hypofibrinogenemia; massive hemorrhage protocol; transfusion medicine.

PubMed Disclaimer

References

REFERENCES

    1. Nascimento B, Goodnough LT, Levy JH. Cryoprecipitate therapy. Br J Anesth. 2014;113(6):922-934.
    1. Callum JL, Karkouti K, Lin Y. Cryoprecipitate: the current state of knowledge. Transfus Med Rev. 2009;23(3):177-188.
    1. Wong H, Curry N. Cryoprecipitate transfusion: current perspectives. Int J Clin Trans Med. 2016;4:89-97.
    1. Pool JG, Gershgold EJ, Pappenhagen AR. High-potency antihaemophilic factor concentrate prepared from cryoglobulin precipitate. Nature. 1964;203:312.
    1. Kasper CK. Judith Graham Pool and the discovery of cryoprecipitate. Haemophilia. 2012;18(6):833-835.

LinkOut - more resources